RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Management of multiple myeloma complicated by hepatitis C virus reactivation
The role of new antiviral therapy
Mahale, P., Thomas, S. K., Kyvernitakis, A., & Torres, H. A. (2016). Management of multiple myeloma complicated by hepatitis C virus reactivation: The role of new antiviral therapy. Open Forum Infectious Diseases, 3(1), ofv211. https://doi.org/10.1093/ofid/ofv211
Reactivation of chronic hepatitis C virus (HCV) infection has been reported in cancer patients receiving chemotherapy. In this study, we report the first case, to our knowledge, of thalidomide-induced acute exacerbation and reactivation of chronic HCV infection complicating management of multiple myeloma. Sofosbuvir-based antiviral therapy helped achieve viral clearance and normalization of liver enzymes, thus allowing access to future potentially life-saving chemotherapy agents.